<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04189588</url>
  </required_header>
  <id_info>
    <org_study_id>TER-QZTR-001</org_study_id>
    <nct_id>NCT04189588</nct_id>
  </id_info>
  <brief_title>Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine</brief_title>
  <acronym>versus</acronym>
  <official_title>A Phase 2 Exploratory Study of Intravenous QUZYTTIR™ (Cetirizine Hydrochloride Injection) Versus Intravenous Diphenhydramine in the Prevention of Hypersensitivity Infusion Reactions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TerSera Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TerSera Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to compare the incidence of infusion reactions to treatment with an&#xD;
      anti-CD20 such as Rituxan® (rituximab) or Taxol® (Paclitaxel) after premedication with&#xD;
      intravenous (IV) QUZYTTIR™ cetirizine hydrochloride (HCl) or IV diphenhydramine during&#xD;
      first-cycle infusion or re-treatment with an anti-CD20 such as Rituxan® (rituximab) or&#xD;
      Paclitaxel. Re-treatment is defined as re-treatment with an anti-CD20 such as Rituxan®&#xD;
      (rituximab) or Paclitaxel after 6 months or in patients with persistent infusion reactions&#xD;
      while on maintenance or retreatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, double-blind exploratory study of IV cetirizine HCl 10 mg/mL&#xD;
      versus IV diphenhydramine 50 mg/mL in approximately 34 patients who require premedication for&#xD;
      hypersensitivity infusion reactions associated with an anti-CD20 such as Rituxan® (rituximab)&#xD;
      or Paclitaxel. The objectives and purpose of the study will be described to patients&#xD;
      presenting at the participating infusion centers. The patients will be randomized to receive&#xD;
      either IV cetirizine HCl or IV diphenhydramine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 25, 2020</start_date>
  <completion_date type="Actual">December 23, 2020</completion_date>
  <primary_completion_date type="Actual">November 23, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Randomized Double Blind Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Hypersensitivity Reactions to Treatment</measure>
    <time_frame>1 Month</time_frame>
    <description>Compare the incidence of infusion reactions (ﬂushing, itching, alterations in heart rate and blood pressure, dyspnea, chest discomfort, acute back or abdominal pain, fever, shaking chills, nausea, vomiting, diarrhea, skin rashes, throat tightening, hypoxia, seizures, dizziness, or syncope) to treatment with anti-CD20 such as Rituxan® (rituximab) or Paclitaxel after premedication with intravenous (IV) QUZYTTIR™ cetirizine hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion or re-treatment after 6 months or in patients with persistent infusion reactions while on maintenance with anti-CD20 such as Rituxan® (rituximab) or Paclitaxel.&#xD;
The infusion reactions will be evaluated following the Common Terminology Criteria for Adverse Events (CTCAE version 5.0) deﬁnitions of graded infusion reactions.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Oncology Patients Receiving Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cetirizine HCl 10 mg/mL: a single 1 mL injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diphenhydramine 50 mg/mL: a single 1 mL injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetirizine HCl 10 mg/mL</intervention_name>
    <description>Comparison of two injectable products: cetirizine HCl 10 mg/mL and diphenhydramine 50 mg/mL, both administered during a 1 to 2-minute period by IV push using a 1 mL syringe</description>
    <arm_group_label>Cohort B</arm_group_label>
    <other_name>Quzyttir™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine 50 mg/mL</intervention_name>
    <description>Comparison of two injectable products: cetirizine HCl 10 mg/mL and diphenhydramine 50 mg/mL, both administered during a 1 to 2-minute period by IV push using a 1 mL syringe</description>
    <arm_group_label>Cohort A</arm_group_label>
    <other_name>Benadryl injection®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-CD20 such as Rituximab or Paclitaxel</intervention_name>
    <description>Compare the incidence of infusion reactions to treatment with an anti-CD20 such as Rituxan® (Rituximab) or Taxol® (Paclitaxel) after premedication with intravenous (IV) QUZYTTIR™ cetirizine hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion or re-treatment. Re-treatment is defined as re-treatment with Rituxan® (Rituximab) or Paclitaxel after 6 months in patients with persistent infusion reactions while on maintenance or re-treatment.</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <other_name>Rituxan®</other_name>
    <other_name>Taxol</other_name>
    <other_name>Arzerra</other_name>
    <other_name>Ocrevus</other_name>
    <other_name>Gazyva</other_name>
    <other_name>Ruxience</other_name>
    <other_name>Truxima</other_name>
    <other_name>Zevalin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients who require treatment premedication with an antihistamine for&#xD;
             hypersensitivity infusion reactions associated with an anti-CD20, such as Rituxan®&#xD;
             (Rituximab) or Paclitaxel, in their first-cycle or re-treatment after 6 months or in&#xD;
             patients with persistent infusion reactions while on maintenance or re-treatment.&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receipt of an investigational drug or device within the past 30 days.&#xD;
&#xD;
          -  Patients with likelihood of developing or history of tumor lysis syndrome.(TLS):&#xD;
             patients with auto-lyse, Burkitt lymphoma and diffuse large B-cell lymphoma (DLBCL)&#xD;
             with bulky disease (single node 7 or more cm or 3 or more nodal sites with size 3 or&#xD;
             more cm)&#xD;
&#xD;
          -  Patients in whom an antihistamine may be contraindicated (e.g., narrow angle glaucoma,&#xD;
             symptomatic prostatic hypertrophy).&#xD;
&#xD;
          -  Patients who, in the opinion of the investigator, may not tolerate an IV injection of&#xD;
             diphenhydramine 50 mg or cetirizine HCl 10 mg.&#xD;
&#xD;
          -  Receipt of any antihistamine (H1 antagonist) within the past 2 hours regardless of the&#xD;
             route of administration, e.g., diphenhydramine, cetirizine, loratadine, fexofenadine,&#xD;
             levocetirizine, desloratadine. chlorpheniramine, clemastine, and doxylamine&#xD;
&#xD;
          -  Receipt of an H2 antagonist within the past 4 hours, e.g., ranitidine, cimetidine,&#xD;
             famotidine, nizatidine.&#xD;
&#xD;
          -  Receipt of doxepin within the past 24 hours; doxepin is an antidepressant, but it also&#xD;
             has antihistamine properties.&#xD;
&#xD;
          -  Receipt of epinephrine (EpiPen® or any other brand) within the past 30 days.&#xD;
&#xD;
          -  Has known allergy to hydroxyzine, cetirizine, or levocetirizine, or diphenhydramine.&#xD;
&#xD;
          -  Pregnant or breastfeeding.&#xD;
&#xD;
          -  Any condition that in the view of the investigator makes the patient unsuitable for&#xD;
             enrollment in this study.&#xD;
&#xD;
          -  Major medical or psychiatric illness, other than diagnosed cancer at the time of&#xD;
             presentation or in the past that in the investigator's judgement they should not be&#xD;
             enrolled in this clinical trial.&#xD;
&#xD;
          -  Inability to provide informed consent.&#xD;
&#xD;
          -  Patients on concomitant P-glycoprotein inhibitors; including antidepressants,&#xD;
             antipsychotics (e.g., olanzapine), and benzodiazepines (e.g., alprazolam), as they may&#xD;
             cause an increase in sedation.&#xD;
&#xD;
          -  Receipt of drugs that cause sedation within the past 24 hours prior to administration&#xD;
             of the study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janine North, B.S.</last_name>
    <role>Study Director</role>
    <affiliation>TerSera Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St.Joseph Heritage Care</name>
      <address>
        <city>Napa</city>
        <state>California</state>
        <zip>94558</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisenhower Medical Center</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Heritage Healthcare</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Consultants</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor, Scott, &amp; White Medical Center</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78665</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor, Scott, &amp; White Medical Center</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor, Scott, &amp; White Medical Center</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 3, 2019</study_first_submitted>
  <study_first_submitted_qc>December 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2019</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Cetirizine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

